<HashMap><database>MassIVE</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://massive-ftp.ucsd.edu/v10/MSV000098529/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Proteomics</omics_type><submitter>Michael Rape</submitter><instrument_platform>Q Exactive GC Orbitrap</instrument_platform><species>Homo Sapiens (ncbitaxon:9606)</species><full_dataset_link>https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?task=37f7b71cf5604b039a5d5432ff2f581d</full_dataset_link><submitter_email>mrape@berkeley.edu</submitter_email><submitter_affiliation>University of California, Berkeley</submitter_affiliation><sample_protocol></sample_protocol><repository>MassIVE</repository><file_size>33</file_size><ptm_modification>MS:1002864 - No post-translational-modifications are included in the identified peptides of this dataset</ptm_modification><data_protocol></data_protocol><pubmed_abstract>The oxidative stress response is centered on the transcription factor NRF2 and protects cells from reactive oxygen species (ROS). While ROS inhibit the E3 ligase CUL3 &lt;sup>KEAP1&lt;/sup> to stabilize NRF2 and elicit antioxidant gene expression, cells recovering from stress must rapidly reactivate CUL3 &lt;sup>KEAP1&lt;/sup> to prevent reductive stress and oxeiptosis-dependent cell death. How cells restore efficient NRF2-degradation upon ROS clearance remains poorly understood. Here, we identify TRIP12, an E3 ligase dysregulated in Clark-Baraitser Syndrome and Parkinson's Disease, as a component of the oxidative stress response. TRIP12 is a ubiquitin chain elongation factor that cooperates with CUL3 &lt;sup>KEAP1&lt;/sup> to ensure robust NRF2 degradation. In this manner, TRIP12 accelerates stress response silencing as ROS are being cleared, but limits NRF2 activation during stress. The need for dynamic control of NRF2-degradation therefore comes at the cost of diminished stress signaling, suggesting that TRIP12 inhibition could be used to treat degenerative pathologies characterized by ROS accumulation.</pubmed_abstract><pubmed_title>Dynamic regulation of the oxidative stress response by the E3 ligase TRIP12.</pubmed_title><pubmed_authors>Ingersoll Andrew J AJ, McCloud Devlon M DM, Hu Jenny Y JY, Rape Michael M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Dynamic regulation of the oxidative stress response by the E3 ligase TRIP12</name><description>NRF2 FLAG IP to determine intracellular interactors</description><dates><publication>Tue Jul 15 17:36:00 BST 2025</publication></dates><accession>MSV000098529</accession><cross_references><pubmed>39651249</pubmed></cross_references></HashMap>